Literature DB >> 24635409

The acute promyelocytic leukaemia success story: curing leukaemia through targeted therapies.

K L Rice1, H de Thé.   

Abstract

The recent finding that almost all patients with acute promyelocytic leukaemia (APL) may be cured using a combination of retinoic acid (RA) and arsenic trioxide (As(2)O(3)) (N Engl J Med, 369, 2013 and 111) highlights the progress made in our understanding of APL pathogenesis and therapeutic approaches over the past 25 years. The study of APL has revealed many important lessons related to transcriptional control, nuclear organization, epigenetics and the role of proteolysis in biological control. Even more important has been the clinical demonstration that molecularly targeted therapy can eradicate disease.
© 2014 The Association for the Publication of the Journal of Internal Medicine.

Entities:  

Keywords:  APL; PML; arsenic trioxide; retinoic acid

Mesh：

Substances：

Year:  2014        PMID： 24635409     DOI： 10.1111/joim.12208

Source DB:  PubMed          Journal:  J Intern Med        ISSN： 0954-6820            Impact factor:   8.989


  10 in total

1.  Induction of proteotoxic stress by the mycotoxin patulin.

Authors:  Angel Guerra-Moreno; John Hanna
Journal:  Toxicol Lett       Date:  2017-05-18       Impact factor: 4.372

Review 2.  Protein Degradation and the Pathologic Basis of Disease.

Authors:  John Hanna; Angel Guerra-Moreno; Jessie Ang; Yagmur Micoogullari
Journal:  Am J Pathol       Date:  2018-10-10       Impact factor: 4.307

3.  Targeted Degradation of Glucose Transporters Protects against Arsenic Toxicity.

Authors:  Marco Jochem; Lukas Ende; Marta Isasa; Jessie Ang; Helena Schnell; Angel Guerra-Moreno; Yagmur Micoogullari; Meera Bhanu; Steven P Gygi; John Hanna
Journal:  Mol Cell Biol       Date:  2019-04-30       Impact factor: 4.272

Review 4.  Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders.

Authors:  Katrina J Falkenberg; Ricky W Johnstone
Journal:  Nat Rev Drug Discov       Date:  2014-08-18       Impact factor: 84.694

5.  Thiol-based direct threat sensing by the stress-activated protein kinase Hog1.

Authors:  Angel Guerra-Moreno; Miguel A Prado; Jessie Ang; Helena M Schnell; Yagmur Micoogullari; Joao A Paulo; Daniel Finley; Steven P Gygi; John Hanna
Journal:  Sci Signal       Date:  2019-11-26       Impact factor: 8.192

6.  Dual Inhibition of HDAC and Tyrosine Kinase Signaling Pathways with CUDC-907 Inhibits Thyroid Cancer Growth and Metastases.

Authors:  Shweta Kotian; Lisa Zhang; Myriem Boufraqech; Kelli Gaskins; Sudheer Kumar Gara; Martha Quezado; Naris Nilubol; Electron Kebebew
Journal:  Clin Cancer Res       Date:  2017-06-09       Impact factor: 12.531

7.  Targeting Transcription Factors in Cancer.

Authors:  Anand S Bhagwat; Christopher R Vakoc
Journal:  Trends Cancer       Date:  2015-09-01

8.  Surface antigen-guided CRISPR screens identify regulators of myeloid leukemia differentiation.

Authors:  Eric Wang; Hua Zhou; Bettina Nadorp; Geraldine Cayanan; Xufeng Chen; Anna H Yeaton; Sofia Nomikou; Matthew T Witkowski; Sonali Narang; Andreas Kloetgen; Palaniraja Thandapani; Niklas Ravn-Boess; Aristotelis Tsirigos; Iannis Aifantis
Journal:  Cell Stem Cell       Date:  2021-01-14       Impact factor: 24.633

Review 9.  Epigenetics in Cancer: A Hematological Perspective.

Authors:  Maximilian Stahl; Nathan Kohrman; Steven D Gore; Tae Kon Kim; Amer M Zeidan; Thomas Prebet
Journal:  PLoS Genet       Date:  2016-10-10       Impact factor: 5.917

10.  PML-RARA mutations confer varying arsenic trioxide resistance.

Authors:  Dong-Mei Bai; Xiao-Feng Zheng
Journal:  Protein Cell       Date:  2017-04       Impact factor: 14.870
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.